Patheon to Showcase Controlled Release Capabilities at CRS 2013
Two poster presentations will be given by Abhijit Gokhale, Ph.D., Senior Scientist, Formulation and Process Development, Patheon Inc., on Monday, July 22 and Tuesday, July 23.
(PRWEB) July 15, 2013
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its controlled release capabilities and softgel technologies at the 40th Annual Meeting & Exposition of the Controlled Release Society (CRS) in Honolulu, Hawaii on July 21 – 24, 2013.
Controlled release technologies often present complex challenges in both development and manufacturing. The scientists at Patheon have years of experience in both of these fields and offer a variety of services and resources to move products from early development to market, while maintaining a longstanding commitment to quality and safety. Patheon offers controlled-release technologies in a multitude of dose forms, including tablets and softgels, to allow customers to cater to their target market and to expand the possible applications of a drug.
Two poster presentations will be given by Abhijit Gokhale, Ph.D., Senior Scientist, Formulation and Process Development, Patheon Inc., on Monday, July 22 and Tuesday, July 23. The presentations will cover extrusion spheronization technique for controlled release of pharmaceutical drugs and formulation development of poorly stable and poorly permeable drugs. Visit http://www.patheon.com for more information.
Patheon representatives will also be available to meet at the CRS conference from July 21 – July 24, 2013 at booth #207, showcasing several of Patheon’s key service offerings. To schedule a meeting in advance send an email to events(at)patheon(dot)com.
Furthermore, Patheon has also recently been published in Drug Development & Delivery’s June 2013 issue; Controlled Release Innovations. Dr. Abhijit Gokhale and Prabal Sundararajan discuss orally disintegrating tablets in their article entitled “Novel Controlled Release Formulation for Orally Disintegrating Tablets Using Ion Exchange Resins.” This publication is just one of many among a library of thought leadership concerning controlled release technologies at Patheon. Visit our Knowledge Library to learn more.
Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.
Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 17 locations, including 13 commercial contract manufacturing facilities and 8 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10924628.htm